Accelerated
Stability Studies

Accelerated stability testing subjects a peptide to elevated temperature, humidity, or light conditions that are more stressful than normal storage. The rationale is thermodynamic: degradation reactions (hydrolysis, oxidation, deamidation, aggregation) follow Arrhenius kinetics, meaning higher temperatures increase reaction rates in a predictable way. By measuring degradation at accelerated conditions, you can extrapolate to estimate how the peptide will behave under normal long-term storage.

Typical accelerated conditions for peptide drug substances include 40 °C / 75% relative humidity (the ICH Q1A accelerated condition for Zone II climates) with testing at 0, 1, 2, 3, and 6 months. Intermediate conditions (25 °C / 60% RH) and stress conditions (60 °C, photostability per ICH Q1B) may also be included depending on the stage of development and intended storage configuration. Samples are pulled at each time point and analyzed by the same methods used for release testing—typically RP-HPLC for purity, SEC for aggregation, and potency assays if available.

The International Council for Harmonisation (ICH) Q1A(R2) guideline provides the framework for pharmaceutical stability testing. While ICH guidelines are written for registered drug products, the principles apply to early-stage peptide development as well. The guideline specifies storage conditions, testing intervals, and minimum study duration for both long-term and accelerated studies. Following ICH conventions—even in preclinical stages—means your stability data will be directly usable when you reach IND-enabling work, avoiding the need to repeat studies under different conditions.

For lyophilized peptides, which represent the majority of peptide drug substances, accelerated stability is particularly informative because lyophilized products are susceptible to moisture uptake, which accelerates chemical degradation. The 75% RH condition in the ICH accelerated protocol directly stresses this vulnerability. Monitoring moisture content alongside chemical purity at each time point reveals whether the closure system maintains the desiccated environment needed for long-term stability.

Accelerated data alone does not assign a shelf life—that requires real-time stability data at the intended storage condition. However, accelerated studies serve two critical functions. First, they provide early warning of degradation pathways: if a peptide shows significant deamidation at 40 °C over 3 months, you know that deamidation will be the shelf-life-limiting degradation in real-time storage, and you can take action (pH adjustment, formulation changes, tighter temperature control). Second, accelerated data supports provisional shelf-life assignments during early development, allowing clinical and commercial planning to proceed in parallel with real-time stability studies.